Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Fermented Stevia Extract Shows Potential Against Pancreatic Cancer Cells, Study Finds
    21 September 2026

    Fermented Stevia Extract Shows Potential Against Pancreatic Cancer Cells, Study Finds

    A research team from Hiroshima University has reported that stevia leaf extract fermented with the plant-derived bacterium Lactobacillus plantarum SN13T demonstrated enhanced anticancer activity against pancreatic cancer cells in laboratory experiments.

    The study, published in the International Journal of Molecular Sciences, investigated whether fermentation could improve the biological activity of stevia leaf extract and identified chlorogenic acid methyl ester (CAME) as an important compound associated with the observed effects.

  • Takeda and Dr. Reddy’s Partner to Promote and Distribute QDENGA® in India’s Private Pediatric and Adult Market
    18 September 2026
    Takeda and Dr. Reddy’s Partner to Promote and Distribute QDENGA® in India’s Private Pediatric and Adult Market
    QDENGA®, across India’s private market for pediatric and adult vaccination in India. Subject to completion of applicable processes with local authorities, the vaccine is anticipated to become available in the first half of 2027.
  • FDA Expands Finerenone Approval to Type 1 Diabetes-Linked Kidney Disease
    18 September 2026
    FDA Expands Finerenone Approval to Type 1 Diabetes-Linked Kidney Disease
    The U.S. Food and Drug Administration (FDA) has approved Kerendia (finerenone) for a new indication in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). Bayer announced it as the first FDA-approved treatment option in more than 30 years for adults with CKD associated with type 1 diabetes
  • FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
    18 September 2026
    FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
    Sanfilippo syndrome type A is a rare inherited disorder that primarily affects the brain and nervous system. Children with the condition can experience progressive loss of cognitive, language and other developmental abilities. Before this approval, there was no FDA-approved treatment specifically designed to address the underlying cause of MPS IIIA
  • India, China and Pakistan Named in US 2027 Major Drug Transit and Production List
    17 September 2026
    India, China and Pakistan Named in US 2027 Major Drug Transit and Production List

    The United States has included India, China and Pakistan among 23 countries designated as major drug transit or major illicit drug-producing countries for fiscal year 2027. The designation was submitted to the U.S. Congress on September 15, 2026, as part of the annual U.S. “Major’s List,” which identifies countries considered significant sources or transit points for illicit drugs entering the United States.

  • Dr. Reddy’s Expands Lenacapavir Partnership With Gilead for Future HIV Prevention Access
    17 September 2026
    Dr. Reddy’s Expands Lenacapavir Partnership With Gilead for Future HIV Prevention Access

    Dr. Reddy’s Laboratories has expanded its collaboration with Gilead Sciences through a royalty-free, non-exclusive voluntary licensing agreement covering investigational once-yearly lenacapavir for HIV prevention. The agreement builds on the companies’ existing 2024 licensing arrangement for lenacapavir and is intended to support future manufacturing readiness, technology transfer and supply planning in licensed territories.

  • Vera Therapeutics Reports Sustained Kidney Function in Phase 3 Trial of TRUTAKNA for IgA Nephropathy
    17 September 2026
    Vera Therapeutics Reports Sustained Kidney Function in Phase 3 Trial of TRUTAKNA for IgA Nephropathy

    Vera Therapeutics has announced final efficacy results from the Phase 3 ORIGIN 3 study of TRUTAKNA™ (atacicept-vymj), reporting sustained stabilization of kidney function and a reduced risk of kidney disease progression in adults with primary IgA nephropathy (IgAN). The final analysis included 428 patients with primary IgAN who were considered at risk of disease progression.

  • Sanofi to Transfer 20 Mature Medicines and 3 Manufacturing Sites to Cheplapharm in Strategic Partnership
    16 September 2026
    Sanofi to Transfer 20 Mature Medicines and 3 Manufacturing Sites to Cheplapharm in Strategic Partnership

    Sanofi and Cheplapharm have announced plans to establish a new strategic partnership focused on the management of mature medicines. Under the proposed agreement, Cheplapharm will take over 20 mature medicines and three Sanofi manufacturing sites worldwide, while Sanofi will receive a 26.4% equity stake in Cheplapharm.

  • FDA Launches Expedited IND Pilot to Speed First-in-Human Clinical Trials
    16 September 2026
    FDA Launches Expedited IND Pilot to Speed First-in-Human Clinical Trials

    The U.S. Food and Drug Administration (FDA) has launched a new Expedited Investigational New Drug (IND) Pilot Program aimed at reducing the time required to move promising drug candidates from development into first-in-human (FIH) clinical trials in the United States.

    Under the pilot, drug sponsors will partner with Qualified Research Institutions (QRIs), which can include academic medical centers, contract research organizations, health networks and other research organizations with relevant scientific and regulatory expertise.

  • MBU Hosts National Conference on Integrating AYUSH with Community Medicine, Advancing Holistic Healthcare
    12 September 2026
    MBU Hosts National Conference on Integrating AYUSH with Community Medicine, Advancing Holistic Healthcare

    Mohan Babu University (MBU) successfully hosted the two-day National Conference on Integrating AYUSH with Community Medicine (IACMI-2026), sponsored by the Indian Council of Social Science Research (ICSSR).

Subscribe to Pharma News